3 stories mentioning KRX:207940Updated just now
Every FINWIRES story that references KRX:207940, newest first.
Samsung Biologics (KRX:207940) secured a biologics contract manufacturing organization (CMO) contract from an undisclosed US-based pharmaceutical company, according to a Wednesday filing with the Korean Exchange.The contract, valued at 835.7 billion won, is valid until Dec. 31, 2031.Shares of Samsung Biologics added over 5% in recent trade on Thursday.
Samsung Biologics (KRX:207940) posted first-quarter net income attributable to shareholders of 469.2 billion won, up 42% from 331.3 billion won a year earlier, according to a Friday filing with the Korea Exchange.The South Korean contract development and manufacturing company's sales jumped 26% year over year to 1.257 trillion won from 999.5 billion won.Shares of Samsung Biologics rose nearly 1% at market close.
Samsung Biologics (KRX:207940) has an average rating of buy and mean price target of 2,199,631.50 won, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
